XTSE
AND
Market cap1.54bUSD
Nov 04, Last price
54.97CAD
Name
Andlauer Healthcare Group Inc
Chart & Performance
P/E
33.37
P/S
3.31
EPS
1.65
Div Yield, %
0.56%
Shrs. gr., 5y
1.60%
Rev. gr., 5y
17.54%
Revenues
650m
+0.39%
Net income
64m
-2.53%
CFO
124m
+19.14%
Dividend
Sep 27, 20240.11 CAD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Andlauer Healthcare Group Inc., a supply chain management company, provides a platform of customized third-party logistics (3PL) and specialized transportation solutions for the healthcare sector in Canada and the United States. The company operates in two segments, Specialized Transportation and Healthcare Logistics. It provides logistics and distribution services, including client and customer integration, transportation and inventory management, distribution and fulfillment, and warehousing solutions; and packaging services, such as co-packing and re-packing, assembly, and custom work services. The company also offers temperature-controlled services; air freight forwarding services; dedicated and last mile delivery services; and ground transportation services, including less-than-truckload, pick-up and delivery, and courier services, as well as carrier options. It provides services to healthcare manufacturers, wholesalers, distributors, 3PL providers, and others through a platform of technology-enabled supply chain solutions for a range of products, including pharmaceuticals, vaccines, biologics, narcotics, precursors, active pharmaceutical ingredients, over-the-counter, cosmetics, health and beauty aids, and medical devices, as well as natural, animal, and consumer health. The company was founded in 1991 and is headquartered in Vaughan, Canada. Andlauer Healthcare Group Inc. opeates as a subsidiary of Andlauer Management Group Inc.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||